Study suggests lorazepam may cut repeat urethral blockage in cats

A new prospective, randomized, double-blinded, placebo-controlled JAVMA study suggests lorazepam may lower the risk of recurrent urethral obstruction in male cats after a first-time obstruction episode. The trial enrolled 80 client-owned male cats seen at a university teaching hospital between 2021 and 2025, excluding cats with urolithiasis or urinary tract infection, and evaluated both recurrence and lower urinary tract signs after hospitalization. The study adds a new data point to a clinical area where post-obstructive recurrence remains common, evidence for drug prevention has been limited, and some previously studied approaches, including prazosin, have produced disappointing or even unfavorable results. (vetlit.org)

Why it matters: Urethral obstruction is a true emergency in cats, with recurrence carrying medical, emotional, and financial consequences for clinics and pet parents alike. For veterinary teams, the significance here is less about replacing standard stabilization and catheter-based management, and more about whether a short-course anxiolytic or urethral relaxation strategy could reduce early reobstruction in carefully selected first-time cases. That question matters because male cats are at particular risk, obstruction can become life-threatening quickly, and current prevention strategies after discharge are still evolving. (vet.cornell.edu)

What to watch: Watch for the full paper’s outcome details, dosing and adverse-event data, and whether clinicians or guideline authors begin discussing lorazepam alongside, or instead of, older post-obstruction medication protocols. (vetlit.org)